Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)

Inclusion Criteria : * Age ≥ 18 years at the time of inclusion, * Diagnosis of primary Sjögren's syndrome according to the 2016 ACR/EULAR classification criteria, * Quantitative measurement of anti-Ro52 antibodies performed as part of routine care, starting from 2020 (date of routine implementation in the laboratory), * Documented medical follow-up in the internal medicine department (or other participating department), * No objection to participation in research after being informed according to current regulations (record of non-opposition if applicable). Exclusion Criteria * Presence of another systemic autoimmune connective tissue disease, including systemic lupus erythematosus, systemic sclerosis, autoimmune myositis, rheumatoid arthritis (except nonspecific arthralgia without classification criteria), * History of solid organ or bone marrow transplantation, * Severe immunosuppression unrelated to Sjögren's syndrome (e.g., HIV infection, ongoing chemotherapy for active hematologic malignancy), * Incomplete or non-exploitable clinical or biological data preventing analysis of primary or secondary endpoints, * Individuals under legal protection measures (e.g., guardianship).